




Director, Addiction Institute of Mount Sinai Icahn School of Medicine at Mount Sinai Depts Psychiatry, Neuroscience and Pharmacological Sciences






COVID: stress, social isolation and drug use





~85,000 drug overdose

National increase in urine drug test positivity rates during COVID-19



Morphine maintenance clinics created (1919-1924)

Treatments for Substance Use Disorders

Alcoholics Anonymous formed (1935)

Model of rehab created (1948-1950)

Disulfiram (1948-1950)

Methadone introduced for addiction (1964)

Drug toxicology (1971)

Narcan (1971)

Naltrexone (1994)

FDA approves buprenorphine for clinical use (2002)

Acamprosate (2004)

Varenicline (Chantix) (2006)


1919

2006

2020

Medications Used To Treat Substance Use Disorder

Only ~17 percent of people who need SUD treatment receive it




Barriers:


Stigma

Governmental regulation
Science-based novel treatments

Behavioral Therapies
Cognitive Behavioral Therapy
Contingency Management
Motivational Enhancement Therapy Group/ Family Therapy







Neurobiology of Addiction



NAc (ventral striatum; Nucleus accumbens): reward expectation; goal-directed behavior

DS (Dorsal striatum): habit formation

PFC (Prefrontal cortex): cognitive control


OFC (orbitofronal cortex): goal-directed behavior, motivational drive; cognitive flexibility

AMG (amygdala): emotional regulation; drugseeking behavior


HIPP (hippocampus): memory


VTA (ventral tegmental area): reward, cognition, emotional regulation

Impaired Cortical Function in Drug-Addicted Subjects and Individuals With Orbitofrontal Cortical Lesions




- Poor decision
- Poor impulse control
- Emotional lability
- Rapid temporal discounting of rewards






Ventral Striatum (nucleus accumbens and reward)



Dorsolateral Striatum = responsible for the stimulus-response (S-R) associations; habitual responding


Associative striatum (caudate nucleus) = Crucial for the learning and expression of goal-directed actions; involved in the selection of actions that lead to reward

Ventral striatum (NAc) = Reinforcement




Reut Avinun et al. J. Neurosci. 2017;37:9724-9729

Amygdala





Craving
Cue reactivity
Emotional regulation




SYNAPTIC (DA) Drug USE EUPHORIA Drug URGES DYSPHORIA

Neurobiology of Addiction







Dopamine
Glutamate
GABA
Opioid
Endocannabinoid




Treatment Development

Human molecular studies

Preclinical Animal Models


Neurobiological targets


Clinical Studies







Molecular Insights: Human Brain








Transcriptional Profile of Heroin Abusers




Dysregulation of Glutamatergic Genes and Epigenetic Remodelers in the Striatum of Human Heroin Abusers



Epi Genetics


Addiction — Complex Disorder




Environment

-control gene activity

Describes the study of mechanisms by which genes are turned on or off without altering their genetic code or DNA sequences.



Dysregulation of Epigenetic Remodelers in the Striatum of Human Heroin Abusers Predict Increased Acetylation and Transcription




More accessible state of DNA = **enhanced transcription**




Increased histone H3 acetylation

- elevated histone acetyl transferase (HAT) levels (e.g., Ncoa1, Ncoa3)

decreased histone deaceylase (HDAC) (e.g., HDAC5)




Epigenetic Marks Related to Transcriptional Activation Correlate to Glutamatergic Impairments




DNA

Translational: Consistent Hyperacetylation in the Rat Heroin Self-administration Model








TSS, transcription start site


Bromodomain and Extraterminal (BET) Inhibitors - Potential Drug Abuse Treatment?




Modified from Taverna and Cole, 2010


Bromodomain and Extraterminal (BET) Inhibitors - Potential Drug Abuse Treatment






Heroin self-administration behavior can be reduced by specific epigenetic inhibitors








Treatment Development - Part II

Human molecular studies

Preclinical Animal Models


Neurobiological targets

Clinical Studies







Epigenetics















Molecular Neurobiology of Opioid Abuse



Increased phosphorylated-Tau in the brains of heroin users







Phosphorylated Tau-Y18




Egervari et al., Nature Communications, 2020

FYN – (tyrosine kinase) is a component of the synaptic machinery that regulates the phosphorylation of Tau; hyperphosphorylated Tau is a pathological feature of neurodegenerative disorders (tauopathies)










destabilization

microtubule



Inhibiting FYN (that reduces pTau) reduces heroin self-administration in animal models






Epigenetic and synaptic regulation target drugs

Clinical Trials



Fyn Expression Regulates Heroin Seeking Behavior

Knockdown of Fyn Reduces Cue-Induced Reinstatement Behavior







Fyn Medication Development

Saracatinib (AZD0530)

Heroin self-administration



AZD0530 Reduces Alcohol Self-Administration and Seeking Behavior



pFYN/FYN (%of Veh/Sal)

250

200

150

100

50

Sal

Alc Veh

AZD


Treatment Development - Part III

Human molecular studies


Preclinical Animal Models

Neurobiological targets

Clinical Studies










Developmental THC Exposure Increases Heroin Self-Administration in Adulthood












Epigenetic Mechanisms


Prenatal and Adolescent THC exposures induce protracted alteration of epigenetic modifications


tone Tails





Synaptic Plasticity






Cannabis contains over 500 chemicals including >140 cannabinoids which have a greater or lesser degree of psycho-pharmaco-activity



THC and CBD: Cannabinoids with Different Actions




CBD Reduces <u>Cue-induced</u> Reinstatement of Heroin-Seeking Behavior




24hr prior to heroin reinstatement session

Cannabidiol







Distinct Effects of THC and CBD On Heroin Vulnerability




Enhance heroin self-adminstration







Heroin Abuse is Characterized by Impairments of Glutamatergic Transmission


Dopamine – reward Glutamate – excitatory neurotransmission; modulate reward system; drug seeking




CBD Normalizes Heroin-Induced Alteration of AMPA Glutamate Receptor








CBD Normalizes Heroin-Induced Alteration of the Cannabinoid CB1 Receptor





Cannabidiol as Potential Treatment Intervention for Opioid Relapse: Double-Blinded Placebo Control Study

Double-blind, Randomized, Placebo-Controlled: Participants with Opioid Use Disorder



Day 1 Day 2 Day 3

Day 10

Prescreen tests

Session 1

Session 2

Session 3

Session 4

•CBD/PI
•Cue tests

Cue testsCBD/PI


•CBD/PI

Cognitive tests

Cue tests


Cue-Induced Effects: Craving VAS-C













Cannabidiol Reduces Cue-induced Physiological Measures of Stress – Cortisol Levels






Cannabidiol Reduces Cue-induced Physiological Measures of Stress – Heart rate








Medical Cannabidiol?




- Cannabidiol holds promise for opioid use disorder treatment craving and anxiety
- Effective dose, treatment regimen....needs to be fully determined
- Treatment for specific features of OUD (and other substances)?
- Formulations/delivery systems need to be developed



Medical Cannabidiol?





Gonzalez-Cuevas et al., Neuropsychopharmacology. 43:2036-2045, 2018


Treatment Development - Part IV

Human molecular studies

Preclinical Animal Models


Neurobiological targets

Clinical Studies





Psychiatric Comorbidity with Substance Use Disorders











Amygdala Dysfunction in Psychiatric Disorders


Dynorphin: opioid neuropeptide; dysphoria





AHA = amygdalohippocampal area
AB = accessory basal nucleus
Co = cortical nuclei
PAC = periamygdaloid cortex

Anderson et al., J. Clinical Investigation, 2013












Prodynorphin mRNA in the Rat PAC is Reduced Following Heroin Self-Administration during the Acute Stress Withdrawal Period










24 hours after self-administration session

DREADD-Assisted Metabolic Mapping (DREAMM)



DREAMM: Whole-brain functional anatomy of PAC Pdyn-expressing cells







Inert agonist targeting the designer receptor






Chemogenetic inhibition of Prodynorphin Neurons in the PAC Activates the Extended Amygdala






Central amygdala, bed nucleus stria terminalis and nucleus accumbens shell (L. Heimer & G. Alheid 1991)

- Roles:
 - Adaptive motivational behaviors
 - Maladaptive response to fear, anxiety and stress
- Dysregulation of the extended amygdala has been implicated in psychiatric disorders







Henrietta Szutorisz Jacqueline Ferland





Gregory Rompala



Alex Chisholm

Michel Miller



Ben Chadwick Claudia Morris







Sharon Spriggs

Nayana Patel

Annie Ly



Yoko Nomura Queens College and **Graduate Center,** CUNY **Lexi Pritchett Patricia Pehme Melissa Huang**



Diana Akpoyibo



Randy Ellis





James Callens Teddy Uzamere



Micah Frier



Joseph Landry



Chris Kudrich Philip Kamilar-Britt Ehsan Moazen-Zadeh Lauren Noble Vyoma Sahani Yuangi Sun

